NASDAQ:XTLB - X T L Biopharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.25 -0.05 (-2.17 %) (As of 03/26/2019 04:00 PM ET)Previous Close$2.3037Today's Range$2.25 - $2.2552-Week Range$1.43 - $3.94Volume2 shsAverage Volume1,700 shsMarket Capitalization$11.57 millionP/E RatioN/ADividend YieldN/ABeta1.02 ProfileDiscussionChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel. Receive XTLB News and Ratings via Email Sign-up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XTLB Previous Symbol CUSIPN/A CIK1023549 Webwww.xtlbio.com Phone972-9955-7080Debt Debt-to-Equity RatioN/A Current Ratio32.39 Quick Ratio32.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.5799 per share Price / Cash Flow3.88 Book Value$1.62 per share Price / Book1.39Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares5,140,000Market Cap$11.57 million Next Earnings Date3/27/2019 (Estimated) OptionableNot Optionable X T L Biopharmaceuticals (NASDAQ:XTLB) Frequently Asked Questions What is X T L Biopharmaceuticals' stock symbol? X T L Biopharmaceuticals trades on the NASDAQ under the ticker symbol "XTLB." When did X T L Biopharmaceuticals' stock split? How did X T L Biopharmaceuticals' stock split work? Shares of X T L Biopharmaceuticals reverse split on Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of X T L Biopharmaceuticals stock prior to the reverse split would have 20 shares after the split. When is X T L Biopharmaceuticals' next earnings date? X T L Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for X T L Biopharmaceuticals. Has X T L Biopharmaceuticals been receiving favorable news coverage? Headlines about XTLB stock have trended somewhat negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. X T L Biopharmaceuticals earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are some of X T L Biopharmaceuticals' key competitors? Some companies that are related to X T L Biopharmaceuticals include BIOLINERX LTD/S (BLRX), VIVUS (VVUS), Aerpio Pharmaceuticals (ARPO), Melinta Therapeutics (MLNT), Leap Therapeutics (LPTX), Aptevo Therapeutics (APVO), Helix Biopharma (HBPCF), Novus Therapeutics (NVUS), Novan (NOVN), AzurRx BioPharma (AZRX), Celsion (CLSN), ProPhase Labs (PRPH), Moleculin Biotech (MBRX), Conatus Pharmaceuticals (CNAT) and Advaxis (ADXS). What other stocks do shareholders of X T L Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X T L Biopharmaceuticals investors own include Supernus Pharmaceuticals (SUPN), Vascular Biogenics (VBLT), Akari Therapeutics (AKTX), TherapeuticsMD (TXMD), Tetraphase Pharmaceuticals (TTPH), T2 Biosystems (TTOO), Verastem (VSTM), Neurocrine Biosciences (NBIX), Synergy Pharmaceuticals (SGYP) and Catalyst Pharmaceuticals (CPRX). Who are X T L Biopharmaceuticals' key executives? X T L Biopharmaceuticals' management team includes the folowing people: Mr. Joshua Levine, Chief Exec. Officer (Age 53)Mr. Itay Weinstein, Chief Financial Officer (Age 48)Mr. Ronen Kantor Adv, Company Sec.Dr. Daphna Paran M.D., Medical Director Who are X T L Biopharmaceuticals' major shareholders? X T L Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Noked Capital LTD (3.87%). Which major investors are buying X T L Biopharmaceuticals stock? XTLB stock was bought by a variety of institutional investors in the last quarter, including Noked Capital LTD. How do I buy shares of X T L Biopharmaceuticals? Shares of XTLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is X T L Biopharmaceuticals' stock price today? One share of XTLB stock can currently be purchased for approximately $2.25. How big of a company is X T L Biopharmaceuticals? X T L Biopharmaceuticals has a market capitalization of $11.57 million. What is X T L Biopharmaceuticals' official website? The official website for X T L Biopharmaceuticals is http://www.xtlbio.com. How can I contact X T L Biopharmaceuticals? X T L Biopharmaceuticals' mailing address is 5 HACHAROSHET ST., RAANANA L3, 43656. The biopharmaceutical company can be reached via phone at 972-9955-7080 or via email at [email protected] MarketBeat Community Rating for X T L Biopharmaceuticals (NASDAQ XTLB)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 59 (Vote Outperform)Underperform Votes: 45 (Vote Underperform)Total Votes: 104MarketBeat's community ratings are surveys of what our community members think about X T L Biopharmaceuticals and other stocks. Vote "Outperform" if you believe XTLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XTLB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What is the QQQ ETF?